ITCI.Intra-cellular Therapies, INC

Form 4: Intra-Cellular Therapies CEO Sharon Mates Reports Stock Transaction

Sentiment:

SEC Form 4 Filing

📋All filings for Intra-cellular Therapies, INC
🔒Login to Follow

Sharon Mates, Chairman, President, and CEO of Intra-Cellular Therapies, reports the conversion of restricted stock units into common stock.

Summary

  • On March 6, 2024, Sharon Mates, Chairman, President, and CEO of Intra-Cellular Therapies, reported a transaction involving the conversion of 40,712 restricted stock units into common stock.
  • Following the transaction, Mates directly owns 1,091,021 shares of common stock.
  • The reported transaction involved restricted stock units granted on March 6, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a transaction. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates activity by the CEO of a publicly traded company in the pharmaceutical sector.

Stakeholder Impact

  • The transaction has a minor impact on shareholders as it reflects the CEO's compensation and ownership stake in the company.

Key Dates

DateDescription
03/06/2023Reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
03/06/2024Transaction date: Conversion of 40,712 restricted stock units into common stock.
03/08/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.